GHRP-6 is most commonly provided in small vials of 5 mg, which should be stored under refrigeration. (It is acceptable however for them to be mailed unrefrigerated.) The vial is diluted with a convenient volume of sterile or bacteriostatic water. For example, the vial might be diluted with 2.5 mL of water, yielding a solution of 2 mg/mL (2000 mcg/mL.) After the water addition, the vial again will be stored under refrigeration.

The delegates have decided to accept the advice of the expert advisory committees that the current scheduling of preparations in Schedules 5 and 6 remains appropriate. The delegates noted the decision to retain listing of teeth whitening preparations containing up to 6 per cent hydrogen peroxide or 18 per cent carbamide peroxide in Schedule 5, or exempt when below 3 per cent and 9 per cent respectively, is to some extent also consistent with the evaluation of such products by the European Commission Scientific Committee on Cosmetics and Non Food Products intended for Consumers (SCCNFP).


In studies GHRP-6 has shown biological actions similar to the naturally occurring hunger stimulating peptide ghrelin. Its main use is to promote food intake by stimulating hunger and aid in energy metabolism. It can be used in the treatment of GH deficiency as well as cachexia, eating disorders and obesity. GHRP-6 is a synthetic met-enkephalin (a naturally occurring opioid growth factor) analog. GHRP-6 contains D-amino acids that are entirely synthetic, lacks opioid activity, and shares no sequence relation with GHRH. It has also been shown that GHRP-6 can lead to re-stimulation of the natural production of HGH.

Side effects resultant from GHRP-6 are typically what would be expected from the use of HGH due to the fact that the end result of GHRP-6 use is that of vastly increased HGH levels. The difference between GHRP-6 and synthetic HGH is, of course, the fact that the HGH resultant from GHRP-6 use is endogenous HGH manufactured by the human body. Nevertheless, GHRP-6 side effects are primarily side effects that occur from HGH use, but there do exist GHRP-6 side effects that are unique to GHRP-6 itself. It is important to note that GHRP-6is not a steroid hormone, nor is it a sex specific hormone, and because of this it can be used by both females and males equally without fear of androgenic or virilization side effects, which GHRP-6 side effects are void of.

The evidence derived from these experiments supports the notion that CD36 is an active and approachable receptor to modulate the healing process. Here we have observed that CD36 occupation by GHRP-6 attenuates wound inflammation, accelerates wound closure, and above all improved wound’s esthetic outcome by impacting ECM proteins accumulation. To our knowledge these findings are unprecedented for GHRP-6 within the context of cutaneous healing.
Now, you may have heard many bodybuilders saying that when you take GHRP-6 that they get a huge and very intense increase in appetite, about 20 mins after the initial injection. Well, this is caused by the GHRP-6 antagonising the peptide Ghrelin, it mimics it, but, in reality, it actually fights against it causing the signal for gastric emptying and hunger. Ghrelin is what many believes causes obesity, and insulin resistance amongst other things, and I believe this is one way by which GHRP-6 may help reduce fat, by fighting against it. However, there is always a but, if you take more than 150mcg the effects of the gastric emptying can be so strong that you may have the urge to severely stuff yourself with food, so if you're on a bulking cycle this is a great side effect, and, considering the price, it's a very cost-effective one. Therefore, during a bulking run, I rate this as the number one aid in increasing appetite, as you also get very a good anabolic effect and increased strength.
Another major difference between GHRP 2 and GHRP 6 is that the former is a bit stronger and releases a lot more Growth Hormone as compared to GHRP 6. Therefore, if increasing Growth Hormone in you is of prime importance then consider choosing GHRP 2 makes a lot of sense. But the importance of the latter in stimulating appetite cannot be ignored altogether. Though GHRP 2 can also be used for the same purpose, it is certainly not in the same level as that of GHRP 6.

Ironically, it only appears that the version of IGF-1 produced in your own muscle has any true anabolic effects. But nonetheless, many folks who’ve used IGF-1 claim to have experienced significant anabolic effects of injections. However, the only evidence for such anabolic effects have been shown in people who are already clinically deficient in IGF-1.
CJC1295 is a 30 amino acid peptide, which primarily functions as a growth hormone releasing hormone analogue (mimicking the effect of GHRH). It was initially invented to treat deep fat deposits in people, because it is known that having an increase in our own growth hormone levels will target this. It stimulates production of our own growth hormone from the pituitary gland.

Taking into account the broad spectrum of TGF-β1 physiology in the fibroblasts/myofibroblasts differentiation events [33], we deem that the reduction of the local scar cellularity and perichondrial matrix accumulation in those animals receiving GHRP-6 could be attributable to TGFB1 transcriptional and functional switch-off. Since the predominant microscopic aspect of the GHRP-6-treated wounds was characterized by meagre cartilage scars, slimmer perichondrium membranes, and far less active cells, we hypothesize that the peptide somehow attenuates the perichondrial activation response to the trauma and/or a possible mesenchyme-to-mesenchyme redifferentiation process, thus lessening the surge of fibroblast and myofibroblasts. In line with this notion, we had documented that GHRP6 prevented hepatic stellate cells activation by reducing CD68, α-SMA, and vimentin local expressions. All these events could be primarily presided by the GHRP-6-related reduction of TGFB1 and CTGF expression in both parenchymal and nonparenchymal cells [7].


Also known as PEG-MGF, this peptide not only helps to promote muscle growth, but also to cause new muscle cells to be formed. The IGF-1 form is linked to polyethylene glycol (PEG), which differentiates it from ordinary mechano growth factor. The implication of this is that the half-life of MGF increases from minutes to days. It is more ideal to use PEG-MGF after workouts. The reason for this is the mechano-sensitive nature of MGF. That means it is activated by mechanical stimulus. The peptide facilitates faster recovery from muscle damage.
Aging often comes with many undesirable effects on our bodies including increased fat, decreased muscle muscle mass and low energy.  Some of these issues can be caused by adult growth hormone deficiency.  Peptide therapies provide a healthy option to reinvigorate the natural release of growth hormone in the body and reverse the negative effects of aging.
In June 2011, the delegate considered a request to restrict the use of chloramphenicol (Schedule 3) to ophthalmic use for the treatment of bacterial conjunctivitis only. The delegate decided that a more restrictive wording of the Schedule 3 chloramphenicol entry would not result in further benefits concerning its ophthalmic use, therefore the wording of the entry remained unchanged.
In studies GHRP-6 has shown biological actions similar to the naturally occurring hunger stimulating peptide ghrelin. Its main use is to promote food intake by stimulating hunger and aid in energy metabolism. It can be used in the treatment of GH deficiency as well as cachexia, eating disorders and obesity. GHRP-6 is a synthetic met-enkephalin (a naturally occurring opioid growth factor) analog. GHRP-6 contains D-amino acids that are entirely synthetic, lacks opioid activity, and shares no sequence relation with GHRH. It has also been shown that GHRP-6 can lead to re-stimulation of the natural production of HGH.
But let’s say you’ve already implemented the IGF-1 boosting strategies of adequate calories, sufficient protein, weight training, plenty of sleep, smart supplementation, mineral intake and alcohol moderation. Should you take the next step, wander into an anti-aging clinic, find an online pharmacy, lurk in the depths of bodybuilding forums, and begin IGF-1 injections?

Hexarelin is a peptide that is derived from GHRP 6, but has been optimized to enhance its metabolic stability. Like the other GHSs, hexarelin increases hGH production, resulting in increased muscle mass, bone density, skin elasticity, and decreased body fat. Unlike the other GHRPs, however, hexarelin does not lead to a substantial increase in ghrelin and therefore does not cause the same appetite stimulation. This peptide has been further promoted for its cardioprotective and regenerative action as well. Hexarelin would be an ideal choice for those looking to benefit from increased growth hormone without appetite stimulation.


To our knowledge, this company collects reviews by asking its customers to share their experiences on Trustpilot. Read more This company has claimed its Trustpilot profile, but to our knowledge, doesn't actively invite its customers to write reviews on Trustpilot. Read more This company hasn't claimed its Trustpilot profile and to our knowledge, doesn't actively invite its customers to write reviews on Trustpilot. Read more
The family of peptidyl growth hormone (GH) secretagogues with broad cytoprotective properties came to light by the American endocrinologist Cyril Bowers, who observed that chemical analogs of enkephalin amide showed GH-releasing activity upon their incorporation to pituitary cultures. GHRP-6 (His-DTrp-Ala-Trp-DPhe-Lys-NH2) appeared as the first in-line synthetic peptide that specifically elicited GH dosage-related release in vitro and in vivo.1 Afterward, a heptapeptide, GHRP-1, and two other hexapeptides, GHRP-2 and hexarelin, were synthesized and addressed by basic and only sporadic clinical studies.
"In circumstances where a medicine is widely known to be used in connection with modifying a physiological process in persons (as appears to be the case with some SARMs and other peptide products), that medicine is likely to satisfy the definition of a therapeutic good despite any disclaimer to the effect that it is for research purposes only and/or not for human use."
Thymosin beta 4 (Tβ4) is the predominant form of thymosin in our bodies. It has been found in high concentrations in wound tissue and certain blood cells involved in clotting, signifying its important role in the healing process. In fact, recent studies have revealed that the first gene to be upregulated after an injury is the Tβ4 gene. As the body begins the recovery process, Tβ4 aids in the creation of new vessels in the injured area, which carry blood, nutrients, and reparative substances to the site. Tβ4 also has anti-inflammatory properties, and works to decrease the amount of inflammatory substances, called cytokines. Inflammation plays a large role in many of the symptoms associated with a large number of conditions (i.e., Lyme disease, CFS, FM, autoimmune diseases, infections, etc.), making the potential impact of Tβ4 quite extensive.
GHRP-6 brings about the effects you’d expect from heightened Growth Hormone and IGF-1 levels; increased fat loss and muscle building. It’s worth remembering that Growth Hormone and IGF-1 will not only promote greater muscle hypertrophy (enlargement of existing muscle fibres) but will also cause muscle hyperplasia – an increase in the actual number of muscle cells.
In 2005, we undertook a porcine model of AMI via left circumflex artery occlusion for 1 hour followed by a 72-hour reperfusion period. GHRP-6 rescued ischemic myocardium from death for over 70% of the area at risk (Figure 3), and that in addition to enhance survival signaling pathways/gene expression of the PI-3K, AKT1, and BCL2 pathways, GHRP-6 decreased reactive oxygen species (ROS) spillover, the inflammatory marker CRP, and preserved the antioxidant defenses.45 These antioxidant and anti-inflammatory properties have also been attributed to GHRP-2 when its antiatherogenic potential was examined in ApoE(−/−) mice so that 12/15-lipoxygenase, interferon gamma, and macrophage migration inhibitory factor (MMF) gene expression were accounted. Furthermore, in cultured aortic smooth muscle cells, GHRP-2 prevented the generation of peroxides, the downregulation of IGF-1 receptor, and the commitment of apoptosis.46
Additionally and not less relevant, GHRP-6 appears as an excellent partner to combine with other molecules (ie, epidermal growth factor [EGF]) because their exclusive actions seem to achieve a kind of synergism, useful to target the multiples nodes of complex pathophysiological processes, and thus to enhance tissue repair processes.56 Garcia del Barco and coworkers in our group have opened unprecedented avenues, by combining GHRP-6 and EGF as a therapeutic approach to ameliorate the damages of multiple sclerosis,57 peripheral axonal pathology,58 and brain ischemia in animal models.59,60 They have demonstrated that in all these experimental substrates the combined action of GHRP-6 and EGF is associated with a better outcome in both clinical and pathological fields.
also using a dose of 400mcg for the IPAM is really a waste of your peptides as anything above saturation dose will give diminished returns, saturation dose(1mcg per kg) is a dose that will give maximum return, if you double the saturation dose then you will not get double the GH pulse in fact no where near that, then the more you use the less added benefit you will get.
White male New Zealand rabbits (4.3–4.5 kg) were used in four independent and extemporaneous experiments. Three to four wounds were created on the ventral side of each ear, down to the surface of the cartilage, using a 6 mm diameter punch biotome (Acuderm) as described [20]. For the surgical procedures, rabbits were anesthetized with intramuscular ketamine (60 mg/kg) and xylazine (5 mg/kg). In order to ensure an exuberant scarring, the perichondrium was carefully scrapped with the surgical blade. The wounds were made on each side of the midline, avoiding the central ear artery and the marginal ear veins. In three experiments, rabbits were randomly assigned to either GHRP-6 (400 μg/mL) treatment or 1% CMC placebo gel. The jelly solutions were administered using 1 mL sterile disposable syringes; 250 μL was applied to each wound, which for the group of GHRP-6 represented an actual dose of 100 μg per wound. Treatments were initiated immediately after surgery and continued thereafter until day 30, when most of the wounds had already completed reepithelialization.
The other submission commented on the consideration to place AOD-9604 in Appendix D. The submission supported listing in Schedule 4, but raised concerns that listing the substance in Appendix D would limit any future development work, including clinical trials that are currently being conducted on the substance. The submitter notes that there are currently 5 clinical trials notified to the TGA using this substance , with these approved clinical trials going ahead on the basis that the substance is safe for human use. Inclusion in Appendix D may place unnecessary burden on those conducting these clinical trials.
Five of the submissions did not support the proposal while the sixth submission did. The former contend that potential risks of inadvertent use of caffeine in those at risk of an adverse event will be increased if selection of an analgesic is made without the assistance or intervention of a healthcare professional. There was also concern that the proposed exemption may result in an increase in liver damage due to excessive consumption of such a product. This was likely to result from people abusing these products as a source of stimulants.
The letters stand for ‘Growth Hormone Releasing Peptide’, and the compound is a peptide in the growth factor family, known as a HEXAPEPTIDE and GH SECRATAGOGUE. It has a strong effect on the release of endogenous (naturally produced) human growth hormone, in a dose related manner. It has been used in school medicine for the treatment of growth hormone deficiency in children and young adults, which drives home just how powerful this compound is at influencing the body to release its own natural GH. It works by signalling the pituitary gland to secrete GH itself, but also by the suppression of SOMATOSTATIN too (an antagonist of growth hormone releasing hormone – GHRH).
Phenylephrine is readily eliminated by sulphate conjugation in the intestinal wall, and oxidative deamination by monoamine oxidative glucuronidation in the liver. Monoamine oxidase (MAO) inhibitors can enhance the limited potential of phenylephrine for cardiac and pressor effects, by reducing metabolism. As a largely specific alpha adrenergic drug, with very weak beta agonism, there is little direct cardiac effect. However, in higher doses, there can be increases in both systolic and diastolic blood pressure and a reflex bradycardia. As an adrenergic agonist there is the potential to interact with other sympathomimetic drugs. In overdose phenylephrine can cause hypertension, headaches seizures tachycardia, and vomiting. There has been no evidence from carcinogenicity studies in rodents of any enhanced cancer risk over prolonged exposure.
Of particular note is the variable chemistry of GHRPs, which consist of three major chemical classes including peptides, partial peptides, and nonpeptides, all of which appear to act via the same receptor and cellular mechanisms. Generally, most GHRPs are active by all routes of administration, specifically intravenously (IV), subcutaneously (SC), orally, intranasally, and intracerebroventricularly (IVC), which supports their possible broad future clinical utility. From evolutionary studies starting with the zebrafish, the natural receptor and hormone have been present for hundreds of years, underscoring the fundamental evolutionary and functional importance of the ghrelin system. GHRPs were well established to act directly on both the hypothalamus and pituitary several years before the GHS receptor assay.23
Everybody has unique goals and these are best adjusted by your dosages. Research in The Journal Of Clinical Endocrinology & Metabolism found 100mcg will saturate all your receptors, but taking 200mcg will cough up an additional 50% of effectiveness, where as 300mcg delivers just a 25% of an additional boost. So the law of diminishing returns is firmly in place with this peptide. What’s more, higher doses were found in a study in The Journal Of Clinical Endocrinology & Metabolism to increase people’s stress hormone, cortisol in doses over a 100mcg so if you do decide to delve into this supplement, stick to the lower doses.
×